An interventional study of World Sight Foundation Field Machine and Comparator in Glaucoma, sponsored by Buckinghamshire Healthcare NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Buckinghamshire Healthcare NHS Trust · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Glaucoma with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Glaucoma · United Kingdom.
Among the 48 studies in Glaucoma with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 48th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →4 of the 48 studies in Glaucoma with a site in United Kingdom are open now. Recruiting first, the newest first:
iSTAR Medical · Sites in United Kingdom, Honduras
Ages 20+
Association for Innovation and Biomedical Research on Light and Image · Sites in United Kingdom, Germany, Italy and 2 more countries
Ages 18+
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 7 · Phase 4 6
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 90 across the 28 interventional studies, 100 across the 20 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 48 have an industry lead sponsor. The 10 most frequent:
Buckinghamshire Healthcare NHS Trust is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Buckinghamshire Healthcare NHS Trust has 1 study filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07009236iSTAR MedicalA Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma | 2026-12 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Glaucoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.
The WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against "the standard" such that an idea of how well it works may be calculated.
This is an exploratory pilot study, to gather information on the use of WSFFM. The investigators do not expect the WSFFM to be equivalent to the HVF and would expect it to be inferior to it; thus, this is not a study of equivalence nor non-inferiority. The trial seeks to instead understand how well the WSFFM works in its purpose of identifying moderate/severe visual field loss in glaucoma patients (which is a different purpose to the HVF analyser, which aims to identify early field loss, as well as monitor for progressive change). The patients the investigators will be investigating will be those attending glaucoma clinic at a single site NHS outpatient hospital eye service. Patients attending glaucoma clinic will have a range of severity of glaucoma (ranging from those in whom a glaucoma diagnosis is still being ascertained, to those with established severe disease) who require assessment by a specialist glaucoma clinician. Patient may not require visual field testing every clinic visit, and not necessarily both eyes (e.g if one eye is blind). The pilot study will be run alongside normal clinical activities. All patients requiring visual fields will be identified in advance of the clinic and approached with a patient information leaflet (detailing the study aims and procedures, and their involvement and rights). Their "trial visit" will be opportunistic as they already will have attended for their appointment; there will be no further follow up after this visit. After their normal initial assessments (as required for all clinical visits), patients will be led to a designated room prior to field testing. Here, an opportunity to answer any queries will be given, before proceeding to consent if the patient wishes to participate. The trial design would most fit a cross-over design. One eye of the participant will be selected at random (unless they were only due for testing of one eye) to have visual fields tested by both devices in a successive time period; the order in which the participants are tested by each device is determined at random. Participants will then undergo visual field testing as per randomisation, for those only clinically requiring one eye testing, they will either undergo WSSFM or HVF testing first, followed by the other (according to randomisation). For those requiring both eyes, the eye to be included will be randomised, in addition to order of device testing for that eye. If the HVF device is randomised first, then one would start with the fellow (non-included) eye to save unnecessary switching between tests.
For example:
The patients will firstly be seated in front of the WSFFM which comprises a box with multiple LED lights inside. There is a chin rest and viewing window through which participants are asked to view the lights inside the device. To first ascertain which brightness of light is required, they will be presented with lights of increasing brightness (three levels) until they can see it; this ensures that those with poor vision throughout their whole visual field - e.g. from a cataract, will still be able to be tested for any superadded visual field loss which might be in keeping with glaucoma. There will be a red light at the centre which participants will be then asked to focus on throughout the test to ensure correct fixation. They will then be shown ten different patterns of lights. These lights will light up in a specific sequence and will not always include the same number of lights. Each time a pattern of lights appears, participants will be asked how many lights they can see; if they see fewer lights than presented, they will be asked where the lights are positioned (left, right, up, down). Their responses will be mapped out by the visual field technician to give a representation of visual field in that eye. Participants will then be thanked for their participation in the trial. They will be given a questionnaire (three questions relating to ease of use, and acceptability of the WSFFM) to complete as they wait to conclude their consultation with the glaucoma clinician (or before they leave, if attending virtual clinic, and further consultation on the day not planned).
There would be no further visit nor contact with the participant required or planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test Device
Device: World Sight Foundation Field Machine
gold standard of care comparator
Other: Comparator
Test Intervention
Gold Standard of Care (Comparator)
Also known as: Humphrey Visual Field Analyser
Validation of the WSFFM - comparing the visual field testing obtained with WSFFM and HVF analyser.
Comparison of visual field measurements obtained using the World Sight Foundation Field Machine (WSFFM) and the Humphrey Visual Field (HVF) analyser. Unit of Measure: Quantitative visual field parameters (e.g., mean deviation or equivalent summary metric, as applicable)
Time frame: Day 1
Feasibility of using the WSFFM in a "real-life" setting
Description: Patient-reported ease of performing the WSFFM test using a numeric rating scale. Unit of Measure: Score on a 1-10 scale (1 = very difficult, 10 = very easy)
Time frame: Day 1
Validation of the WSFFM - comparing the visual field testing obtained with WSFFM and HVF analyser.
Description: Patient-reported comparison of ease of use between WSFFM and HVF testing. Unit of Measure: Ordinal or categorical comparison (e.g., WSFFM easier / same / HVF easier)
Time frame: Day 1
Quantitative data obtained from the mean (and standard deviation) of patient reported acceptability and ease of testing on a sliding scale of 0-10; compared with HVF score using Students t-test.
Time frame: Day 1
Qualitative data obtained from patient reported outcomes in relation to their experience of visual field testing using the WSFFM.
Time frame: Day 1
The mean time taken to complete WSFFM testing, compared to the mean time for HVF analyser testing, using paired Student's t-test to provide quantitative data
Time frame: Day 1
Field technician qualitative data regarding ease of use, collected over time after each clinical session.
Time frame: Day 1
Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 2 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 2 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Buckinghamshire Healthcare NHS Trust